Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=23 Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC
Phase 2 N=80 Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Phase 2 N=66 E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=342 Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Patients Maintaining Stable Disease or Objective Response 2 Months After Randomization — 0; 0; 27; 7 participants — p=0.005
Phase 2 N=86 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 18; 34; 28 percentage of participants
Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Phase 2 N=38 Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: 18 Week Progression-free Survival Rate — 35; 72 percentage of participants
Phase 2 N=63 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Phase 2 N=81 Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Response Rate — 10; 10 percentage of participants
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=82 Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Phase 2 N=25 AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Phase 2 N=39 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Phase 2 N=60 AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts…
Phase 2 N=37 Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Response by RECIST Criteria (v 1.0) — 3; 5; 11; 15 participants
Phase 2 N=79 Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma · Lung Adenocarcinoma
Primary: PFS (Progression Free Survival) — 8; 20 months
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=52 Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Time to Progression — 3.12; 1.64 months
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 3 N=583 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
Phase 2 N=50 Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: Time to Progression — 123 days
Phase 2 N=13 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Progression Free Survival(PFS) — 5.6 months
Phase 2 N=36 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cetuximab — 750 mg/m^2 every 21 days
Phase 2 N=11 Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 2; 0 participants